{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:27:15Z","timestamp":1786602435404,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) is a highly complex clinical syndrome associated with significant morbidity and mortality. Its underlying mechanisms are poorly understood, treatment options are limited, the disease burden on patients is substantial, and clinical outcomes are poor. Previous clinical studies have preliminarily suggested that Shengxian Yixin Granule (SXYX) is an effective herbal formula for the treatment of HFpEF, but it lacks high-quality clinical evidence. This study therefore plans to conduct a randomized controlled trial (RCT) to evaluate the efficacy and safety of SXYX in treating HFpEF, aiming to provide a new therapeutic strategy for this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. It will be conducted at four Chinese medicine hospitals in China. A total of 148 eligible patients with HFpEF will be enrolled and randomly assigned in a 1:1 ratio to the SXYX group or the placebo group. The SXYX group will receive Shengxian Yixin Granule, while the placebo group will receive a matching placebo. Both groups will receive standard Western medical therapy as background treatment. The treatment duration for all groups is 24 weeks. The primary outcome is the change in peak VO\n                      <jats:sub>2<\/jats:sub>\n                      (assessed by cardiopulmonary exercise testing) from baseline to 24 weeks. Secondary outcome measures include the change in peak oxygen uptake from baseline to 12 weeks, NT-proBNP, echocardiographic parameters, NYHA functional class, 6-minute walk test distance (6MWT), Traditional Chinese Medicine (TCM) syndrome scale, major symptoms and signs, EQ-5D score, and coagulation function. These outcomes will be used to evaluate the efficacy of SXYX. Routine blood, urine, and stool tests, liver and kidney function tests, electrocardiograms, and adverse events will be used to assess the safety of SXYX. Wearable monitoring devices will be used for out-of-hospital, dynamic, and multidimensional assessment of patients\u2019 exercise tolerance, including heart rate, blood oxygen saturation, step count, and walking distance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will evaluate the efficacy and safety of SXYX in treating HFpEF. The findings will provide a scientific basis for the clinical application of SXYX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/itmctr.ccebtcm.org.cn<\/jats:ext-link>\n                      , identifier ITMCTR2026000833.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1902637","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:33:15Z","timestamp":1786599195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of Shengxian Yixin Granule for treating heart failure with preserved ejection fraction: a study protocol for a multicenter, randomized, double-blind, placebo-controlled trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaozhen","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"First School of Clinical Medicine, Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"First School of Clinical Medicine, Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janru","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1093\/eurheartj\/ehac248","article-title":"An update on global epidemiology in heart failure","volume":"43","author":"Becher","year":"2022","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12906-025-05106-3","article-title":"Effectiveness and safety analysis of Qifu Yixin prescription for the treatment of heart failure with preserved ejection fraction: study protocol for a randomized, double-blind, placebo-controlled clinical trial","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Complement Med Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e012432","DOI":"10.1161\/CIRCHEARTFAILURE.124.012432","article-title":"Ubiquity of multimorbidity: comorbid conditions and mortality in HFpEF","volume":"18","author":"Kamat","year":"2025","journal-title":"Circ Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"158099","DOI":"10.1016\/j.phymed.2026.158099","article-title":"Mahuang decoction targets fluid retention in heart failure with preserved ejection fraction","volume":"155","author":"Liang","year":"2026","journal-title":"Phytomedicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1154167","DOI":"10.3389\/fphar.2023.1154167","article-title":"Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms","volume":"14","author":"Fan","year":"2023","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3389\/fphys.2018.01420","article-title":"The effect of Chinese herbal medicine on quality of life and exercise tolerance in heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Wang","year":"2018","journal-title":"Front Physiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1255940","DOI":"10.3389\/fcvm.2023.1255940","article-title":"Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials","volume":"10","author":"Guo","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.13288\/j.11-2166\/r.2025.08.017","article-title":"Expert consensus on diagnosis and treatment of heart failure with preserved ejection fraction with integrated traditional Chinese and western medicine","volume":"66","author":"Zhu","year":"2025","journal-title":"J Tradit Chin Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/jama.2025.4486","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomized trials","volume":"334","author":"Chan","year":"2025","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/S0140-6736(25)00672-5","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"405","author":"Hopewell","year":"2025","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jama.2020.26812","article-title":"Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"325","author":"Mueller","year":"2021","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101101","DOI":"10.1016\/j.jacadv.2024.101101","article-title":"Percent predicted peak exercise oxygen pulse provides insights into ventricular-vascular response and prognosticates HFpEF","volume":"3","author":"Li","year":"2024","journal-title":"JACC Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.13359\/j.cnki.gzxbtcm.2024.12.010","article-title":"Effect of Shenqi granules on the prognosis of patients with heart failure with preserved ejection fraction of qi deficiency and blood stasis pattern","volume":"41","author":"Liu","year":"2024","journal-title":"J Guangzhou Univ Tradit Chin Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.13288\/j.11-2166\/r.2023.07.016","article-title":"Chronic heart failure traditional Chinese medicine diagnosis and treatment guideline (2022)","volume":"64","year":"2023","journal-title":"J Tradit Chin Med (Chin Ed)"},{"key":"B26","unstructured":"Bethesda, MD\n          National Institutes of Health\n          Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0\n          \n          2025"},{"key":"B27","unstructured":"Geneva\n          International Council for Harmonisation\n          ICH Harmonised Guideline: Statistical Principles for Clinical Trials E9(R1) \u2013 Addendum: Estimands and Sensitivity Analysis in Clinical Trials. Step 4 Version\n          \n          2019"},{"key":"B28","first-page":"235","article-title":"Chinese guidelines for the diagnosis and treatment of heart failure 2024","volume":"52","year":"2024","journal-title":"Chin J Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1093\/eurheartj\/ehs221","article-title":"EACPR\/AHA joint scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations","volume":"33","author":"Guazzi","year":"2012","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pcad.2018.10.003","article-title":"Determining cardiorespiratory fitness with precision: compendium of findings from the FRIEND registry","volume":"62","author":"Kaminsky","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.122.062832","article-title":"Sex differences in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: insights from DAPA-HF and DELIVER","volume":"147","author":"Wang","year":"2023","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1142\/S0192415X23500568","article-title":"Total flavonoids of astragalus inhibit activated CD4+ T cells and regulate differentiation of Th17\/Th1\/Treg cells in experimental autoimmune encephalomyelitis mice by JAK\/STAT and NF\u03baB signaling pathways","volume":"51","author":"Han","year":"2023","journal-title":"Am J Chin Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"116128","DOI":"10.1016\/j.jep.2022.116128","article-title":"Research progress of natural medicine Astragalus mongholicus bunge in treatment of myocardial fibrosis","volume":"305","author":"Ren","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B36","first-page":"467","article-title":"Effect and mechanism of total paeony glycoside on airway remodeling in bronchial asthma","volume":"50","author":"Zhou","year":"2025","journal-title":"Med J Chin People\u2019s Lib Army"},{"key":"B37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.19664\/j.cnki.1002-2392.250085","article-title":"Research progress on the mechanism of Trichosanthes, Chinese chive and Pinellia decoction on myocardial extracellular matrix remodeling","volume":"53","author":"Niu","year":"2025","journal-title":"Acta Chin Med Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.13820\/j.cnki.gdyx.20231281","article-title":"Pharmacological effect of gualouxiebai banxia decoction on improving lipid metabolism in hyperlipidemic mice","volume":"44","author":"Fan","year":"2023","journal-title":"Guangdong Med J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.13412\/j.cnki.zyyl.20250929.009","article-title":"Research progress on the anti-inflammatory effect and mechanism of cinnamaldehyde","author":"Zhou","year":"2026","journal-title":"Pharmacol Clin Chin Mater Med"},{"key":"B40","first-page":"442","article-title":"Effect of aqueous extract from descurainiae semen on ventricular remodeling in heart failure model rats based on PI3K\/Akt\/mTOR signaling pathway","volume":"29","author":"Yang","year":"2019","journal-title":"Zhejiang J Integr Tradit Chin West Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.19879\/j.cnki.1005-5304.202412149","article-title":"Effect of Shengxian Yixin Granule on ventricular remodeling in rats with myocardial infarction based on PI3K\/AKT signaling pathway","volume":"32","author":"Zhang","year":"2025","journal-title":"Chin J Inf Tradit Chin Med"},{"key":"B42","first-page":"1786","article-title":"Effects of endurance exercise training on peak oxygen consumption and diastolic function in patients with heart failure with preserved ejection fraction","volume":"32","author":"Qiu","year":"2021","journal-title":"Hainan Med J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12906-025-05029-z","article-title":"Efficacy and safety of Qishen granule for treating heart failure with preserved ejection fraction: a study protocol for a multicenter, randomized, double-blind, placebo-controlled trial","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Complement Med Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"Eur Heart J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.jchf.2024.05.022","article-title":"NT-proBNP: lower is always better-even in HFpEF","volume":"12","author":"Bayes-Genis","year":"2024","journal-title":"JACC Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1902637\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:33:23Z","timestamp":1786599203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1902637\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":45,"alternative-id":["10.3389\/fcvm.2026.1902637"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1902637","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1902637"}}